Latest total revenue for OXFD: $57M, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2020
Trailing 12 months ending Sep 2020
The latest total revenue for OXFD is $57M as of September 2020. That compares with $71M in the prior-year period — down 19.3% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Oxford Immunotec Global PLC's historical trend and sector peers before judging valuation or financial health.
Over the past year, OXFD's total revenue moved from $71M to $57M — a 19.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oxford Immunotec Global PLC's operating scale or balance-sheet position.
Against Healthcare companies, OXFD currently prints $57M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Oxford Immunotec Global PLC's growth, margins, and balance sheet.
A total revenue figure of $57M for OXFD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.
After noting OXFD's total revenue ($57M), review year-over-year change from $71M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.